-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Supplementary Application for Consistency Evaluation of Chlorphenamine Maleate Injection by Shijiazhuang Sihua Pharmaceutical Group Approved
Category:
发布时间：2024-01-09
【概要描述】
On January 9, the supplementary application for the consistency evaluation of Shijiazhuang Sihua Pharmaceutical Group’s Chlorphenamine Maleate Injection (2 mL: 20 mg and 1 mL: 10 mg) was approved by the National Medical Products Administration, with both strengths having successfully passed the consistency evaluation. To date, Shijiazhuang Sihua has had a total of 91 product specifications across 70 varieties approved under the consistency evaluation program, including 17 specifications that were the first in China to receive such approval.
On January 9, the supplementary application for the consistency evaluation of Shijiazhuang Sihua Pharmaceutical Group’s Chlorphenamine Maleate Injection (2 mL: 20 mg and 1 mL: 10 mg) was approved by the National Medical Products Administration, with both strengths having successfully passed the consistency evaluation. To date, Shijiazhuang Sihua has had a total of 91 specifications across 70 products pass the consistency evaluation, including 17 specifications that were the first in China to do so. According to reports, chlorphenamine maleate injection is primarily used to treat allergic rhinitis and may also be employed for common cold or sinusitis, allergic reactions of the skin and mucous membranes, as well as for the management of drug eruptions and contact dermatitis.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091